Menu Search
Equities

Allarity Therapeutics Inc

ALLR:NAQ

Allarity Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.21
  • Today's Change-0.05 / -2.21%
  • Shares traded332.76k
  • 1 Year change-99.53%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Allarity Therapeutics Inc had revenues remain flat at 0.00, though the company grew net income from a loss of 16.06m to a smaller loss of 11.90m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-52.54%
Return on equity-190.32%
Return on investment-110.73%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Allarity Therapeutics Inc fell by 1.86m. Cash Flow from Financing totalled 11.00m or -- of revenues. In addition the company used 12.75m for operations while cash from investing was breakeven.
Cash flow per share-100.64
Price/Cash flow per share--
Book value per share16.98
Tangible book value per share8.80
More ▼

Balance sheet in USDView more

Allarity Therapeutics Inc has a Debt to Total Capital ratio of 6.26%.
Current ratio2.01
Quick ratio--
Total debt/total equity0.0668
Total debt/total capital0.0626
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.